TRAC and neoplasm: Eyquem et al., demonstrated that employing the use of a CRISPR/CAS9 system to direct a CD19-specific CAR to the T-cell receptor α constant (TRAC) locus results in uniform CAR expression in T cells, enhances T-cell potency, with improved anti-tumor activity compared to conventional CAR T cells [130].